Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Xeris Biopharma Inc.

    NASDAQ: XERS · Real-Time Price · USD
    4.36
    -0.06 (-1.36%)
    At close: Jun 13, 2025, 3:59 PM

    Xeris Biopharma Statistics

    Share Statistics

    Xeris Biopharma has 160.16M shares outstanding. The number of shares has increased by 3.83% in one year.

    Shares Outstanding

    n/a
    		 160.16M

    Shares Change (YoY)

    n/a
    		 3.83%

    Shares Change (QoQ)

    n/a
    		 3.26%

    Owned by Institutions (%)

    n/a
    		 44%

    Shares Floating

    n/a
    		 147.61M

    Failed to Deliver (FTD) Shares

    n/a
    		 27,436

    FTD / Avg. Volume

    n/a
    		 0.95%

    Short Selling Information

    The latest short interest is 17.6M, so 10.99% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 17.6M

    Short % of Shares Out

    n/a
    		 10.99%

    Short % of Float

    n/a
    		 11.43%

    Short Ratio (days to cover)

    n/a
    		 9.96

    Valuation Ratios

    The PE ratio is -9.07 and the forward PE ratio is 44.15. Xeris Biopharma's PEG ratio is 0.51.

    PE Ratio

    n/a
    		 -9.07

    Forward PE

    n/a
    		 44.15

    PS Ratio

    n/a
    		 2.45

    Forward PS

    n/a
    		 1.5

    PB Ratio

    n/a
    		 -16.8

    P/FCF Ratio

    n/a
    		 -13.15

    PEG Ratio

    n/a
    		 0.51
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Xeris Biopharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.67, with a Debt / Equity ratio of -9.17.

    Current Ratio

    n/a
    		 1.67

    Quick Ratio

    n/a
    		 1.19

    Debt / Equity

    n/a
    		 -9.17

    Debt / EBITDA

    n/a
    		 -24.01

    Debt / FCF

    n/a
    		 -7.17

    Interest Coverage

    n/a
    		 -1.01

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $515,406.09

    Profits Per Employee

    n/a
    		 $-139,177.66

    Employee Count

    n/a
    		 394

    Asset Turnover

    n/a
    		 0.63

    Inventory Turnover

    n/a
    		 0.76

    Taxes

    Income Tax

    n/a
    		 -2.27M

    Effective Tax Rate

    n/a
    		 3.97%

    Stock Price Statistics

    The stock price has increased by 98.18% in the last 52 weeks. The beta is 0.91, so Xeris Biopharma's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.91

    52-Week Price Change

    n/a
    		 98.18%

    50-Day Moving Average

    n/a
    		 4.55

    200-Day Moving Average

    n/a
    		 3.77

    Relative Strength Index (RSI)

    n/a
    		 41.55

    Average Volume (20 Days)

    n/a
    		 2,894,174

    Income Statement

    In the last 12 months, Xeris Biopharma had revenue of 203.07M and earned -54.84M in profits. Earnings per share was -0.37.

    Revenue

    n/a
    		 203.07M

    Gross Profit

    n/a
    		 166.24M

    Operating Income

    n/a
    		 -33.65M

    Net Income

    n/a
    		 -54.84M

    EBITDA

    n/a
    		 -11.3M

    EBIT

    n/a
    		 -26.62M

    Earnings Per Share (EPS)

    n/a
    		 -0.37
    Full Income Statement

    Balance Sheet

    The company has 71.62M in cash and 271.45M in debt, giving a net cash position of -199.83M.

    Cash & Cash Equivalents

    n/a
    		 71.62M

    Total Debt

    n/a
    		 271.45M

    Net Cash

    n/a
    		 -199.83M

    Retained Earnings

    n/a
    		 -671.86M

    Total Assets

    n/a
    		 315.45M

    Working Capital

    n/a
    		 68.42M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -36.98M and capital expenditures -868K, giving a free cash flow of -37.85M.

    Operating Cash Flow

    n/a
    		 -36.98M

    Capital Expenditures

    n/a
    		 -868K

    Free Cash Flow

    n/a
    		 -37.85M

    FCF Per Share

    n/a
    		 -0.26
    Full Cash Flow Statement

    Margins

    Gross margin is 81.86%, with operating and profit margins of -16.57% and -27%.

    Gross Margin

    n/a
    		 81.86%

    Operating Margin

    n/a
    		 -16.57%

    Pretax Margin

    n/a
    		 -28.12%

    Profit Margin

    n/a
    		 -27%

    EBITDA Margin

    n/a
    		 -5.57%

    EBIT Margin

    n/a
    		 -16.57%

    FCF Margin

    n/a
    		 -18.64%

    Dividends & Yields

    XERS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for XERS is $6.5, which is 49.1% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $6.5

    Price Target Difference

    n/a
    		 49.1%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -0.9

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist